SPTLC2 Gene

SPTLC2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPTLC2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SPTLC2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Serine Palmitoyltransferase Long Chain Base Subunit 2</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>SPT2, SPT small subunit 2, LCB2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>14q31.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>9517</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166800</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O15270</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>610313</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Enzyme; Lipid metabolism</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>HSAN1, Alzheimer's disease, Parkinson's disease</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Serine supplementation</td>
<td>Reduce 1-deoxysphingolipid production</td>
</tr>
<tr>
<td class="label">SPT inhibitors</td>
<td>Reduce toxic lipid production</td>
</tr>
<tr>
<td class="label">Ceramide modulators</td>
<td>Target downstream effects</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore normal SPT function</td>
</tr>
</table>

SPTLC2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPTLC2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SPTLC2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Serine Palmitoyltransferase Long Chain Base Subunit 2</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>SPT2, SPT small subunit 2, LCB2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>14q31.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>9517</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166800</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O15270</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>610313</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Enzyme; Lipid metabolism</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>HSAN1, Alzheimer's disease, Parkinson's disease</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Serine supplementation</td>
<td>Reduce 1-deoxysphingolipid production</td>
</tr>
<tr>
<td class="label">SPT inhibitors</td>
<td>Reduce toxic lipid production</td>
</tr>
<tr>
<td class="label">Ceramide modulators</td>
<td>Target downstream effects</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore normal SPT function</td>
</tr>
</table>

SPTLC2 (Serine Palmitoyltransferase Long Chain Base Subunit 2) encodes the small subunit (sPTLC2) of serine palmitoyltransferase (SPT), the rate-limiting enzyme in de novo sphingolipid biosynthesis. Located on chromosome 14q31.3, SPTLC2 forms a heterodimer with SPTLC1 to catalyze the condensation of serine and palmitoyl-CoA, producing 3-ketosphinganine—the first step in sphingolipid synthesis. Mutations in SPTLC2 cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), while dysregulated sphingolipid metabolism is implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and various neurodegenerative conditions.

Overview

Gene Structure

The SPTLC2 gene spans approximately 21 kb and consists of 12 exons encoding a 422-amino acid protein. The protein contains an N-terminal transmembrane domain and a C-terminal catalytic domain facing the cytosol.

Protein Structure

SPTLC2 contains several functional domains[@sptlc2_structure]:

Function

Serine Palmitoyltransferase Activity

SPTLC2 is the catalytic subunit of serine palmitoyltransferase:

• Heterodimer formation — SPTLC2 pairs with SPTLC1 to form the functional enzyme
• Substrate binding — Binds serine and palmitoyl-CoA in the active site
• Catalytic activity — Mediates the condensation reaction:
• Palmitoyl-CoA + L-serine → 3-ketosphinganine + CoA + CO₂
• Substrate specificity — SPTLC2 determines the chain length specificity of the enzyme

Sphingolipid Biosynthesis Pathway

SPTLC2 initiates the sphingolipid biosynthesis pathway:

Palmitoyl-CoA + Serine → 3-Ketosphinganine → Sphinganine → Dihydroceramide → Ceramide
↓
Sphingosine → Sphingosine-1-phosphate
↓
Ceramide → Sphingomyelin, Glycosphingolipids

Cellular Functions

The products of SPTLC2 activity serve critical functions:

• Membrane composition — Sphingolipids are essential components of eukaryotic membranes, particularly in lipid rafts[@lipid_rafts]
• Cell signaling — Ceramide acts as a pro-apoptotic second messenger; sphingosine-1-phosphate (S1P) is pro-survival[@s1p_neuroprotection]
• Stress response — Ceramide accumulation triggers ER stress, autophagy, and apoptosis
• Myelin formation — Sphingolipids are major components of the myelin sheath[@myelin_sphingolipids]
• Neuronal function — Sphingolipids regulate synaptic plasticity, receptor function, and neurotransmitter release[@synapse_sphingolipids]

Brain Expression

SPTLC2 is expressed in various brain regions:

• Cerebral cortex — Neurons and astrocytes
• Hippocampus — CA1-CA3 regions, dentate gyrus ([memory](/diseases/alzheimers-disease))
• Cerebellum — Purkinje cells
• Substantia nigra — [Dopaminergic neurons](/diseases/parkinsons-disease)
• Peripheral nerves — Sensory and autonomic neurons
• Oligodendrocytes — For [myelin](/cell-types/oligodendrocytes) synthesis

Regulation

SPTLC2 activity is regulated at multiple levels:

• Transcriptional regulation — SPTLC2 expression is induced by ER stress and cellular starvation
• Allosteric regulation — Product inhibition by ceramide and downstream sphingolipids
• Post-translational modification — Phosphorylation affects enzyme activity
• Substrate availability — Palmitoyl-CoA and serine levels control flux through the pathway

SPTLC2 in Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)

SPTLC2 mutations cause HSAN1B (OMIM 613640)[@sptlc2_hsnn1]:

• Inheritance — Autosomal dominant
• Pathogenic mutations — Missense mutations (e.g., V144M, G387A) reduce SPT activity
• Phenotype — Progressive sensory loss, pain insensitivity, ulcerations, mutilations
• Autonomic features — Some patients have autonomic dysfunction

Molecular Mechanism in HSAN1

The pathogenesis involves a toxic gain-of-function mechanism[@sptlc2_hsan1_mechanism][@sptlc2_alanine]:

The accumulation of 1-deoxysphingolipids is toxic to peripheral sensory and autonomic neurons, causing the characteristic neuropathy phenotype.

SPTLC2 in Alzheimer's Disease

SPTLC2 dysregulation is implicated in [Alzheimer's disease](/diseases/alzheimers-disease) through multiple mechanisms[@sphingolipid_ad][@ad_ceramide]:

Ceramide Accumulation

Elevated ceramide levels are observed in AD brain:

• Ceramide concentrations increase with disease progression
• Ceramide promotes amyloid-beta generation[@amyloid_ceramide]
• Ceramide induces neuronal apoptosis[@ceramide_neurons]

Amyloid-β Effects

Amyloid-β induces sphingolipid metabolism changes:

• Aβ increases ceramide synthesis
• Aβ disrupts sphingolipid rafts
• Ceramide amplifies Aβ toxicity

ER Stress and Apoptosis

Ceramide accumulation triggers neuronal dysfunction[@er_stress_ceramide]:

• Triggers unfolded protein response (UPR)
• Activates caspase-dependent apoptosis
• Impairs protein quality control

Synaptic Dysfunction

Sphingolipid alterations affect synaptic plasticity[@synapse_sphingolipids]:

• Reduces synaptic density
• Impairs neurotransmitter release
• Affects receptor trafficking

Tau Pathology

Ceramide promotes tau pathology[@tau_ceramide]:

• Promotes tau phosphorylation
• Enhances tau aggregation
• Contributes to neurofibrillary tangle formation

SPTLC2 in Parkinson's Disease

SPTLC2 may contribute to [Parkinson's disease](/diseases/parkinsons-disease)[@pd_ceramide]:

Dopaminergic Vulnerability

Sphingolipid metabolism is altered in the substantia nigra:

• Ceramide levels increase in dopaminergic neurons
• SPT activity is dysregulated
• Alterations affect neuronal survival

Alpha-Synuclein Interactions

Membrane lipid composition affects α-syn aggregation:

• Sphingolipids influence α-syn membrane binding
• Ceramide promotes α-syn oligomerization
• Lipid rafts may serve as aggregation platforms

Mitochondrial Dysfunction

Ceramide induces mitochondrial apoptosis:

• Ceramide translocates to mitochondria
• Triggers cytochrome c release
• Activates caspase cascade

Neuroinflammation

Sphingolipids modulate glial activation:

• Ceramide activates microglia
• Promotes inflammatory cytokine release
• Contributes to neuroinflammation

Other Neurodegenerative Disorders

• Amyotrophic lateral sclerosis — Altered sphingolipid metabolism in motor neurons
• Huntington's disease — Ceramide dysregulation in striatal neurons
• Multiple sclerosis — Demyelination involves sphingolipid alterations
• Niemann-Pick disease — Genetic defects in sphingolipid catabolism

Lipid Rafts and Neuronal Signaling

Lipid rafts are specialized membrane microdomains enriched in sphingolipids and cholesterol. In neurons, lipid rafts serve crucial functions[@lipid_rafts]:

Synaptic Function

• Neurotransmitter receptor localization
• Synaptic vesicle organization
• Signal transduction platforms

Pathological Implications

• Aβ interaction with lipid rafts
• α-syn membrane binding sites
• Membrane protein aggregation

Therapeutic Targeting

• Modulating raft composition
• Disrupting pathological protein-lipid interactions
• Restoring membrane homeostasis

Mitochondrial Sphingolipid Biology

Ceramide directly affects mitochondrial function[@mitophagy_ceramide]:

Ceramide-Mitochondria Interaction

• Ceramide translocates to mitochondrial outer membrane
• Promotes permeabilization
• Releases pro-apoptotic factors

Mitophagy Regulation

• Ceramide influences PINK1/Parkin pathway
• Modulates mitochondrial quality control
• Affects neuronal survival

Therapeutic Implications

• Targeting ceramide-mitochondria axis
• Preserving mitochondrial function
• Preventing cell death

Summary

SPTLC2 encodes the catalytic subunit of serine palmitoyltransferase, the rate-limiting enzyme in de novo sphingolipid biosynthesis. Mutations in SPTLC2 cause hereditary sensory and autonomic neuropathy type 1 (HSAN1) through toxic 1-deoxysphingolipid accumulation. Beyond this rare disease, dysregulated sphingolipid metabolism contributes to common neurodegenerative conditions including Alzheimer's and Parkinson's disease. The enzyme's role in ceramide production links it to multiple pathological processes including ER stress, mitochondrial dysfunction, synaptic loss, and neuroinflammation. Therapeutic targeting of SPTLC2 and downstream sphingolipid pathways holds promise for treating both rare and common neurodegenerative disorders.

Therapeutic Implications

SPTLC2 is a potential therapeutic target for multiple conditions:

Serine Supplementation Therapy

High-dose L-serine has shown promise in HSAN1[@sptlc2_therapy]:

• Competes with aberrant amino acid substrates
• Reduces 1-deoxysphingolipid synthesis
• May improve sensory function

Ceramide Modulation

Targeting ceramide metabolism in neurodegeneration:

• Ceramide synthase inhibitors
• Glucosylceramide synthase modulators
• S1P receptor agonists

Research Methods

Lipidomics

• Mass spectrometry-based lipid profiling
• Quantification of ceramide species
• Spatial lipid mapping in brain tissue

Cellular Models

• Primary neuronal cultures
• iPSC-derived neurons
• Transgenic cell lines

Animal Models

• SPTLC2 knockout mice
• HSAN1 mutant mouse models
• Transgenic AD/PD models

Cross-Links

Related Genes

• [SPTLC1](/genes/sptlc1) — Partner subunit in serine palmitoyltransferase

Related Mechanisms

• [Sphingolipid Metabolism](/mechanisms/sphingolipid-metabolism)
• [Ceramide Signaling](/mechanisms/ceramide-signaling)
• [ER Stress in Neurodegeneration](/mechanisms/er-stress-neurodegeneration)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)

Related Diseases

• [Hereditary Sensory Neuropathy](/diseases/hereditary-sensory-neuropathy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

See Also

• [SPTLC1](/genes/sptlc1)
• [Sphingolipid Metabolism](/mechanisms/sphingolipid-metabolism)
• [Hereditary Sensory Neuropathy](/diseases/hereditary-sensory-neuropathy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Ceramide Signaling](/mechanisms/ceramide-signaling)
• [Myelin](/cell-types/oligodendrocytes)

External Links

• [NCBI Gene: SPTLC2](https://www.ncbi.nlm.nih.gov/gene/9517)
• [UniProt: O15270](https://www.uniprot.org/uniprot/O15270)
• [OMIM: 610313](https://www.omim.org/entry/610313)
• [GTEx Portal: SPTLC2](https://gtexportal.org/home/gene/SPTLC2)
• [GeneCards: SPTLC2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SPTLC2)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SPTLC2 Gene discovered through SciDEX knowledge graph analysis: